Xeris Pharmaceuticals Stock Discussion

$Xeris Pharmaceuticals (XERS.US)$
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
4 minutes ago, 4:00 AM PST
Via BusinessWire
XERS
Share
Full-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million
Year-end 2024 cash position expected to be over $71 million, generating positive cash flow in the fourth quarter
Recorlev® net revenue Q4 2024 anticipated to increase by approximately $5 million or 28% sequentially
2024 financial results ...

$Xeris Pharmaceuticals (XERS.US)$ when will we see a new record high?

$Xeris Pharmaceuticals (XERS.US)$ Xeris Biopharma Reports Preliminary Q2 Total Revenue To Exceed $47M, Representing Over 23% Growth Over Last Year; Estimate $44.894M

$Xeris Pharmaceuticals (XERS.US)$ And you were doing so lovely! Oh well still a nice PI on fairly benign PR as far as a catalyst for moving up

$Xeris Pharmaceuticals (XERS.US)$ Xeris Biopharma Holdings Inc - FDA End-of-Phase 2 Interaction to Facilitate a Phase 3 Pivotal Study Program Is Expected by Year-End

$Xeris Pharmaceuticals (XERS.US)$
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
Xeris Biopharma announced positive topline results from its Phase 2 study of XP-8121, a once-weekly subcutaneous levothyroxine (SC) formulation. The study showed that XP-8121 provides predictable bioavailability and sustained levothyroxine levels, achieving normalized TSH/T4 levels with 45% less drug...

$Xeris Pharmaceuticals (XERS.US)$ Reuters· 1 min ago
Xeris Biopharma: Potential to Get Development Payments, Plus Low Double-Digit Royalties Based on Future Sales of Xeris Glucagon for Pumps, Pump Systems